ANGO at a glance
ANGIODYNAMICS INC (ANGO, SEC CIK 1275187) filed its latest 10-K annual report on July 14, 2026, a 10-Q quarterly report on April 2, 2026, an 8-K current report on July 14, 2026 and Form 4 insider filings as recently as July 31, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended May 31, 2026 (FY2026), ANGIODYNAMICS INC (ANGO) reported revenue of $320.2 million (up 9.5% from FY2025) and a net loss of $36.7 million. Diluted EPS was -$0.88.
- As of June 30, 2026, 28 institutional investment managers tracked by SignalX reported holding ANGIODYNAMICS INC (ANGO) shares worth $162.2 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Nighan Warren JR on July 30, 2026 of 23,370 shares at $14.72 per share.
- In the last 90 days, ANGO insiders reported 0 open-market purchases ($0) and 1 open-market sale ($344K) on Form 4, a net sale of $344K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2026
- $320.2M
- +9.5% vs prior year
- Insiders · 90 days
- 0 buys · 1 sell
- Net −$344K
- 13F holders
- 28 funds
- $162.2M · +0 vs prior quarter
- Latest 8-K
- Jul 14, 2026
- Item 2.02 · Item 7.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended May 31, 2026
Business Overview
- Core business model: design, manufacture, and sale of innovative medical devices for cardiovascular disease and cancer treatment
- New product emphasis: expanded FDA clearance for NanoKnife System prostate tissue ablation in Dec 2024 and MDR CE mark in Feb 2026 for multiple tumor ablations
- Strategic shift: divestiture of dialysis, BioSentry (June 2023), and PICC/Midline businesses (Feb 2024); discontinuation of RadioFrequency Ablation and Syntrax lines
- Quantitative metric: workforce reduced to approximately 632 full-time employees as of May 31, 2026
- Noteworthy fact: ongoing regulatory challenges delaying FDA clearances amid increased testing requirements and expanded MDR compliance through 2027-2028
Risk Factors
- Regulatory risk: FDA increased scrutiny on Quality System Regulation compliance and post-market requirements following July 2025 enactment of the One Big Beautiful Bill Act
- Geopolitical risk: $0.7M revenue exposed to Iran distributors amid U.S. sanctions and rising Middle East conflicts impacting global trade and tariffs
- Supply chain vulnerability: Transition of manufacturing to third-party sites in U.S., Costa Rica, Latvia, Italy, Israel, China by Q1 FY2027 with risk of disruptions and increased costs
- Competitive risk: Price competition intensified by growing purchasing power of GPOs and IDNs, risking contract losses and reduced profitability
- Financial risk: CEO transition planned by Nov 2026 poses leadership uncertainty potentially impacting operations and investor confidence
Management Discussion & Analysis
- Revenue $320.2M, up 9.5% YoY ($292.5M in FY 2025); Med Tech grew 18.4% ($150.0M) strongest, Med Device up 2.6% ($170.2M)
- Gross margin 54.6% vs 53.9% YoY; Med Tech margin 63.6% vs 62.0%, Med Device margin declined 46.7% vs 47.7%
- Net loss increased to $36.7M from $34.0M; loss per share widened to $0.88 from $0.83
- Operating cash flow positive $3.1M vs negative $10.1M prior year; capex $2.6M plus $3.4M on unit placements; $1.7M stock buybacks in FY 2025, none in FY 2026
- Management pursuing restructuring to save $15M annually by FY 2027; share repurchase authorization $15M with $13.3M remaining; key risks include inflation, tariffs, supply chain disruptions
AI summary of the ANGO 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Feb 28, 2026
Management Discussion & Analysis
- Revenue $78.4M, up 8.9% YoY from $72.0M
- Gross margin 52.9% vs 54.0% YoY; net loss $8.1M vs $4.4M
- Best segment Med Tech revenue $37.3M, up 19.0%; worst Med Device growth 1.2%
- Cash $37.8M vs $55.9M; operating cash use $14.4M vs $28.9M
- Headwinds from tariffs, inflation, labor shortages, supply-chain challenges and backlog; liquidity sufficient for 12 months
Risk Factors
- No risk-factors section provided; supplied text covers Items 2–6
- CEO James C. Clemmer transition and retirement agreement dated February 3, 2026
- Retention incentive letters disclosed February 3, 2026
- No senior-security defaults during the quarter
- No public repurchases under the $15.0 million authorization during the quarter
AI summary of the ANGO 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Item 2.02 contains only a regulatory incorporation disclaimer
- No earnings figures, reporting-period results, or operational metrics provided
Item 7.01: Regulation FD Disclosure
- Forward-looking statements cover future financial performance, strategy, products, costs, capital expenditures, and growth opportunities
- No operating results, guidance figures, or new business developments disclosed in the provided text
Item EX-99.1: Item EX-99.1
- FY2026 revenue $320.2M, up 9.4%, led by Med Tech growth of 18.4% to $150.0M
- Adjusted EBITDA $13.2M versus $7.6M, signaling improved operating leverage despite GAAP loss of $36.7M
Item 8.01: Other Events
- AngioDynamics filed a patent infringement lawsuit against Endovascular Engineering in Delaware federal court on April 23, 2026
- Dispute concerns E2’s Hēlo Thrombectomy System and AngioDynamics’ self-expanding funnel technology patents
Item 2.02: Results of Operations and Financial Condition
- Item 2.02 language only addresses regulatory treatment of the disclosure
- No operating results, financial figures, or fiscal-year performance metrics included in the provided text
Item 7.01: Regulation FD Disclosure
- Forward-looking statements cover AngioDynamics’ strategy, financial outlook, products, growth opportunities, and operating plans
- Key risks include FDA actions, clinical-trial results, competition, healthcare reforms, litigation, recalls, and product liability
AI summaries of ANGO 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ANGO
Don't miss the next ANGO filing
- Alerts as it files. A push when ANGO files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ANGO, by share count.
- Ask anything. An AI agent that reads every ANGO filing and answers with sources.
ANGO alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Nighan Warren JR | Sell | Jul 30, 2026 | 23,370 | $14.72 |
| Trowbridge Stephen A | M | Jul 22, 2026 | 57,381 | - |
| Nighan Warren JR | M | Jul 22, 2026 | 5,694 | - |
| Trowbridge Stephen A | M | Jul 22, 2026 | 16,296 | - |
| Piccinini Laura | F | Jul 22, 2026 | 4,506 | $13.82 |
| Piccinini Laura | M | Jul 22, 2026 | 8,047 | - |
| Nighan Warren JR | M | Jul 22, 2026 | 20,052 | - |
| Nighan Warren JR | F | Jul 22, 2026 | 1,671 | $13.82 |
Financial SummaryXBRL
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $292.5M | $320.2M |
| Gross Profit | - | $157.7M | $174.9M |
| Operating Income | - | -$40.0M | -$39.9M |
| Net Income | - | -$34.0M | -$36.7M |
| Gross Margin | - | 53.9% | 54.6% |
| Op. Margin | - | -13.7% | -12.5% |
| Net Margin | - | -11.6% | -11.5% |
| Balance Sheet | |||
| Total Assets | $317.7M | $280.1M | $267.2M |
| Equity | $205.6M | $183.0M | $170.8M |
| ROE | - | -18.6% | -21.5% |
| Per Share | |||
| EPS | - | $-0.83 | $-0.88 |
| Cash Flow | |||
| Operating CF | - | -$10.1M | $3.1M |
| CapEx | - | $4.5M | $2.6M |
Source: XBRL data in ANGIODYNAMICS INC (ANGO)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate ANGO share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 28 | $162.2M |
| Q1 2026 | 28 | $138.1M |
| Q4 2025 | 26 | $160.3M |
| Q3 2025 | 27 | $143.2M |
| Q2 2025 | 29 | $127.2M |
| Q1 2025 | 24 | $91.5M |
| Q4 2024 | 21 | $96.0M |
| Q3 2024 | 17 | $58.4M |
- AQR Capital Management+337.6K (+134%)
- JPMorgan Chase & Co+204.4K (+1246%)
- Millennium Management+138.4K (+21%)
- BlackRock+117.3K (+3%)
- Two Sigma Investments+75.8K (+33%)
- State Street Corp−375.7K (-28%)
- Bank of America Corp−158.5K (-31%)
- Renaissance Technologies LLC−69.4K (-9%)
- Citadel Advisors LLC−35.8K (-74%)
- Vanguard Capital Management LLC−32.1K (-2%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 200 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ANGO filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Jul 31, 2026 | - | - | - |
| 4 | Jul 24, 2026 | - | - | - |
| 4 | Jul 24, 2026 | - | - | - |
| 4 | Jul 24, 2026 | - | - | - |
| 4 | Jul 24, 2026 | - | - | - |
| 4 | Jul 24, 2026 | - | - | - |
| 4 | Jul 22, 2026 | - | - | - |
| 4 | Jul 22, 2026 | - | - | - |
| 4 | Jul 22, 2026 | - | - | - |
| 4 | Jul 22, 2026 | - | - | - |
| 4 | Jul 22, 2026 | - | - | - |
| 4 | Jul 22, 2026 | - | - | - |
| 4 | Jul 22, 2026 | - | - | - |
| 4 | Jul 22, 2026 | - | - | - |
| 4 | Jul 22, 2026 | - | - | - |
| 4 | Jul 22, 2026 | - | - | - |
| 4 | Jul 22, 2026 | - | - | - |
| 4 | Jul 22, 2026 | - | - | - |
| 4 | Jul 21, 2026 | - | - | - |
| 4 | Jul 21, 2026 | - | - | - |
| 4 | Jul 21, 2026 | - | - | - |
| 4 | Jul 21, 2026 | - | - | - |
| 4 | Jul 21, 2026 | - | - | - |
| 4 | Jul 21, 2026 | - | - | - |
| 8-K | Jul 14, 2026 | - | Analysis | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
- SKIN · Beauty Health CoSurgical & Medical Instruments & Apparatus
ANGO SEC filings: frequently asked questions
Are ANGO insiders buying or selling?
In the last 90 days, ANGIODYNAMICS INC (ANGO) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $344,006 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold ANGO stock?
As of June 30, 2026, the largest ANGIODYNAMICS INC (ANGO) holders among the 13F filers tracked by SignalX were BlackRock ($49.5 million), Vanguard Capital Management LLC ($22.0 million), Dimensional Fund Advisors ($12.6 million), State Street Corp ($12.5 million), Millennium Management ($10.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ANGO's revenue in fiscal year 2026?
For the fiscal year ended May 31, 2026 (FY2026), ANGIODYNAMICS INC (ANGO) reported revenue of $320.2 million (up 9.5% from FY2025) and a net loss of $36.7 million. Diluted EPS was -$0.88. The figures come from the XBRL data in the 10-K.
What are the main risks in ANGO's latest 10-K?
In the 10-K filed July 14, 2026, ANGIODYNAMICS INC (ANGO) flagged: Regulatory risk: FDA increased scrutiny on Quality System Regulation compliance and post-market requirements following July 2025 enactment of the One Big Beautiful Bill Act. Geopolitical risk: $0.7M revenue exposed to Iran distributors amid U.S. sanctions and rising Middle East conflicts impacting global trade and tariffs. (AI summary of the Risk Factors section.)
What did ANGO report in its latest 8-K?
ANGIODYNAMICS INC (ANGO) filed an 8-K on July 14, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). Item 2.02 contains only a regulatory incorporation disclaimer.
What are the latest ANGO SEC filings?
ANGIODYNAMICS INC (ANGO) filed its latest 10-K annual report on July 14, 2026, a 10-Q quarterly report on April 2, 2026, an 8-K current report on July 14, 2026 and a Form 4 insider filing on July 31, 2026.
What is ANGO's SEC CIK number?
ANGIODYNAMICS INC (ANGO)'s SEC Central Index Key (CIK) is 1275187. EDGAR lists every ANGO filing under that number.
Ask anything about ANGO
The research agent reads ANGO's filings, financials, insider trades and 13F holders, then answers with sources.